R. Okan Akar after graduating from the Molecular Biology and Genetics Department of Istanbul Kültür University, where he graduated with a second degree in 2017, completed his master's degree in Cancer Biology and Pharmacology at Istinye University. He is currently doing his doctorate in the molecular oncology program of Istinye University. He is also co-founder of Ovoboard Biyoteknoloji A.Ş. During his master’s, he worked as an intern at the Karolinska Institute Oncology-Pathology department in Sweden. He has been involved in laboratory studies for more than six years from the undergraduate le...
R. Okan Akar after graduating from the Molecular Biology and Genetics Department of Istanbul Kültür University, where he graduated with a second degree in 2017, completed his master's degree in Cancer Biology and Pharmacology at Istinye University. He is currently doing his doctorate in the molecular oncology program of Istinye University. He is also co-founder of Ovoboard Biyoteknoloji A.Ş. During his master’s, he worked as an intern at the Karolinska Institute Oncology-Pathology department in Sweden. He has been involved in laboratory studies for more than six years from the undergraduate level. He is working on molecular cancer pathways, anti-cancer drug discovery, and cell death. He is a member of the Molecular Cancer Research Association (MOKAD) and EACR (European Association for Cancer Research). He has published 10 articles in international journals. In addition to being a research assistant at Istinye University Medical Faculty Medical Biochemistry Department, he also works at Istinye University Molecular Cancer Research Center (ISUMKAM). His hobbies include science fiction-fantastic literature and basketball.
Articles
A novel 1,4-naphthoquinone-derived compound induces apoptotic cell death in breast cancer cells
, 2019
Propolis-loaded photocurable methacrylated pullulan films: Evaluation of mechanical, antibacterial, biocompatibility, wound healing and pro-angiogenic abilities
, 2024
Biocompatible silver nanoparticles from apricot kernel skin: a green synthesis approach to antibacterial and antiangiogenic therapies
, 2024
Pd(II) and Pt(II) saccharinate complexes with two phosphine derivatives: Synthesis, anticancer and antiangiogenic activities
, 2024
Targeting Periostin Expression Makes Pancreatic Cancer Spheroids More Vulnerable to Natural Killer Cells
, 2023
Synthesis, Characterization and Apoptosis Capabilities of a Novel Naphthoquinone-Derived Compound in Triple-Negative Breast Cancer
, 2023
Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines
, 2022
Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines
, 2022
The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells
, 2019
Highly Promising Antitumor Agent of a Novel Platinum(II) Complex Bearing a Tetradentate Chelating Ligand
, 2020
Synthesis, DNA Binding and Cytotoxic Activity of Newcopper(II) Complexes of Trisubstituted Imidazoles
, 2022
Key actors in cancer therapy: epigenetic modifiers
, 2019
A promising therapeutic combination for metastatic prostate cancer: Chloroquine as autophagy inhibitor and palladium(II) barbiturate complex
, 2020
Key actors in cancer therapy: epigenetic modifiers
, 2019
Reports
Effect of p53 on Diclofenac and Ibuprofen-induced ROS generation-dependent apoptosis on PC3 prostate cancer cells - AKAR REMZİ OKAN,RENCÜZOĞULLARI ÖZGE,ARISAN ELİF DAMLA,OBAKAN YERLİKAYA PINAR,ÇOKER GÜRKAN AJDA
Diclofenac increased ROS generation to proceed EMT processes p53 independently in PC3 cells - AKAR REMZİ OKAN,RENCÜZOĞULLARI ÖZGE,ARISAN ELİF DAMLA,OBAKAN YERLİKAYA PINAR,ÇOKER GÜRKAN AJDA,PALAVAN ÜNSAL NARÇİN
A newly synthesized platinum complex as a potent antitumor drug candidate - ERKISA MERVE,AKAR REMZİ OKAN,SELVİ SELİN,ULUKAYA ENGİN
